Dr. Murrough is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1 Gustave L Levy Pl
Box 1230
New York, NY 10029Phone+1 212-241-6539Fax+1 212-241-3354- Is this information wrong?
Summary
- Dr. James Murrough is Associate Professor of Psychiatry and Neuroscience and Director of the Depression and Anxiety Center for Discovery and Treatment at the Icahn School of Medicine at Mount Sinai. He is a faculty member of the Friedman Brain Institute and Center of Excellence in Neuropharmacology at Mount Sinai. Dr. Murrough conducts clinical and translational research aimed at understanding the biological basis of mood and anxiety disorders in order to point the way towards new, more effective treatments. He received his Bachelor of Science in Neuroscience and Behavioral Biology from Emory University in Atlanta and his Medical degree from Tufts University School of Medicine in Boston. He completed residency training in psychiatry, a research fellowship in experimental therapeutics and clinical neuroscience, and a PhD in clinical research from Mount Sinai. Dr. Murrough has received research support from the National Institutes of Health, the Doris Duke Charitable Foundation, the American Foundation for Suicide Prevention, the Dana Foundation and the Brain and Behavior Research Foundation. He is a Member of the American College of Neuropsychopharmacology and an active member of the scientific community. In addition to his research and educational activities, Dr. Murrough oversees a clinical program at Mount Sinai focused on evidence-based treatments for treatment-resistant depression and other refractory forms of mood and anxiety disorders.
Education & Training
- Icahn School of Medicine at Mount SinaiFellowship, Research, 2009 - 2011
- Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Psychiatry, 2005 - 2009
- Tufts University School of MedicineClass of 2005
Certifications & Licensure
- NY State Medical License 2007 - 2026
- American Board of Psychiatry and Neurology Psychiatry
Clinical Trials
- Continuation Ketamine in Major Depression Start of enrollment: 2007 Oct 01
- Cysteamine Therapy for Major Depressive Disorder Start of enrollment: 2008 Jul 01
- Treatment Study of Bipolar Depression Start of enrollment: 2009 Jul 01
- Join now to see all
Publications & Presentations
PubMed
- Circulating myeloid-derived MMP8 in stress susceptibility and depression.Flurin Cathomas, Hsiao-Yun Lin, Kenny L Chan, Long Li, Lyonna F Parise, Johana Alvarez, Romain Durand-de Cuttoli, Antonio V Aubry, Samer Muhareb, Fiona Desland, Yusuke...> ;Nature. 2024 Feb 1
- 3 citationsSocial stress induces autoimmune responses against the brain.Yusuke Shimo, Flurin Cathomas, Hsiao-Yun Lin, Kenny L Chan, Lyonna F Parise, Long Li, Carmen Ferrer-Pérez, Samer Muhareb, Sara Costi, James W Murrough, Scott J Russo> ;Proceedings of the National Academy of Sciences of the United States of America. 2023 Dec 5
- Development and initial validation of the Mount Sinai Resilience Scale.Jonathan M DePierro, Deborah B Marin, Vanshdeep Sharma, Craig L Katz, Robert H Pietrzak, Adriana Feder, James W Murrough, Sydney Starkweather, Brian P Marx, Steven M S...> ;Psychological Trauma. 2024 Mar 1
- Join now to see all
Journal Articles
- Effects of the KCNQ Channel Opener Ezogabine on Functional Connectivity of the Ventral Striatum and Clinical Symptoms in Patients with Major Depressive DisorderKatherine A Collins, Dan V Iosifescu, James W Murrough, Eric J Nestler, Nisha Chadha, Nature
- Double-Blind, Placebo-Controlled, Dose-Ranging Trial of Intravenous Ketamine as Adjunctive Therapy in Treatment-Resistant Depression (TRD)Sanjay J Mathew, Madhukar H Trivedi, Lee C Chang, Dan V Iosifescu, Manish K Jha, Maurizio Fava, Marlene P Freeman, Cristina Cusin, James Murrough, George I Papakostas,..., Nature
- High-Dose Ondansetron Reduces Activation of Interoceptive and Sensorimotor Brain RegionsEvan Leibu, Wayne K Goodman, James W Murrough, Barbara J Coffey, Nature
- Join now to see all
Authored Content
- F142. Effect of Treatment Resistance Status on Whole Brain Voxel-Based Morphometry in Major Depressive DisorderApril 2018
Press Mentions
- Ketamine Beats Shock Therapy in Easing Tough-to-Treat DepressionMay 25th, 2023
- AAGP Session to Highlight Research on Resilience, Emotional Well-Being in AgingJanuary 27th, 2023
- Plastic Surgeons Are Using Ketamine to Make Nose Jobs More PleasantJanuary 18th, 2022
- Join now to see all
Hospital Affiliations
- The Mount Sinai HospitalNew York, New York
External Links
- Depression and Anxiety Centerhttp://www.icahn.mssm.edu/dac
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: